MarketCap
Facebook
X
Telegram
Check-Cap Ltd. Net Income | CHEK
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Check-Cap Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.14 M | -25.1 M | -17.6 M | -19.1 M | -17.2 M | -13.8 M | -13.8 M | -10.6 M | -9.77 M | -8.83 M | -12.3 M | -610 K | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.14 M | -25.1 M | -12.1 M |
Quarterly Net Income Check-Cap Ltd.
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.14 M | 5.21 M | -25.1 M | -6.31 M | -17.6 M | -6.88 M | - | - | - | - | - | - | -3.92 M | -3.57 M | - | - | -2.89 M | -3.43 M | - | - | -3.36 M | -3.15 M | - | - | -2.66 M | -2.13 M | - | - | -2.83 M | - | - | - | -1.99 M | - | - | - | -2.44 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.21 M | -25.1 M | -4.64 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Diagnostics research industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Interpace Biosciences
IDXG
|
24.6 M | $ 6.47 | 2.11 % | $ 28.6 M |  USA |
 |
Organovo Holdings
ONVO
|
-13.8 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
23.6 M | - | -16.95 % | $ 1.54 M | USA |
 |
PerkinElmer
PKI
|
241 M | - | -0.91 % | $ 14.7 B | USA |
 |
Soleno Therapeutics
SLNO
|
20.9 M | - | - | $ 2.69 B | USA |
 |
Enzo Biochem
ENZ
|
-26.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
Biomerica
BMRA
|
-3.78 M | $ 1.69 | 0.6 % | $ 4.93 M | USA |
 |
Myriad Genetics
MYGN
|
-366 M | $ 6.03 | 3.52 % | $ 558 M | USA |
 |
Pacific Biosciences of California
PACB
|
-546 M | $ 2.25 | 6.64 % | $ 675 M | USA |
 |
Neuronetics
STIM
|
-39 M | $ 2.26 | 7.11 % | $ 149 M | USA |
 |
Agilent Technologies
A
|
1.3 B | $ 175.77 | 1.56 % | $ 49.9 B | USA |
 |
Charles River Laboratories International
CRL
|
-144 M | $ 357.54 | 3.52 % | $ 17.7 B | USA |
 |
Fulgent Genetics
FLGT
|
-60.5 M | $ 20.23 | 0.65 % | $ 623 M | USA |
 |
Guardant Health
GH
|
-416 M | $ 173.31 | 2.5 % | $ 21.7 B | USA |
 |
Accelerate Diagnostics
AXDX
|
-50 M | - | -61.36 % | $ 2.46 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
877 M | $ 328.03 | -0.28 % | $ 27.3 B | USA |
 |
Lantheus Holdings
LNTH
|
234 M | $ 99.94 | 0.14 % | $ 6.74 B | USA |
 |
Mettler-Toledo International
MTD
|
869 M | $ 1 666.34 | -0.24 % | $ 34.3 B |  Schweiz |
 |
ENDRA Life Sciences
NDRA
|
-7.03 M | $ 4.82 | 0.42 % | $ 3.79 M | USA |
 |
NeoGenomics
NEO
|
-108 M | $ 16.7 | 0.63 % | $ 2.14 B | USA |
 |
Neogen Corporation
NEOG
|
-7.9 M | $ 12.22 | 0.21 % | $ 2.66 B | USA |
 |
National Research Corporation
NRC
|
11.6 M | $ 22.54 | 2.78 % | $ 505 M | USA |
 |
Natera
NTRA
|
-208 M | $ 404.77 | 0.2 % | $ 55.3 B | USA |
 |
Burning Rock Biotech Limited
BNR
|
-55.3 M | $ 11.74 | -0.68 % | $ 123 M |  China |
 |
OPKO Health
OPK
|
-226 B | $ 1.63 | 1.23 % | $ 1.22 B | USA |
 |
Trinity Biotech plc
TRIB
|
-31.2 M | $ 7.3 | -0.06 % | $ 2.62 B |  Irlanda |
 |
T2 Biosystems
TTOO
|
-50.1 M | - | -39.35 % | $ 313 K | USA |
 |
Bioventus
BVS
|
22.7 M | $ 14.75 | -1.44 % | $ 983 M | USA |
 |
Biocept
BIOC
|
-32.1 M | - | -13.05 % | $ 7.29 M | USA |
 |
Precipio
PRPO
|
-363 K | $ 19.5 | -2.55 % | $ 31.3 M | USA |
 |
Akumin
AKU
|
-157 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
QIAGEN N.V.
QGEN
|
425 M | $ 50.36 | -0.07 % | $ 10.9 B |  Niderland |
 |
RadNet
RDNT
|
-18.6 M | $ 69.9 | -0.63 % | $ 5.26 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
897 M | $ 26.55 | -1.28 % | $ 25.2 B | Niderland |
 |
Senseonics Holdings
SENS
|
-69.1 M | $ 7.46 | -0.67 % | $ 311 M | USA |
 |
Sotera Health Company
SHC
|
77.9 M | $ 18.35 | 1.35 % | $ 5.21 B | USA |
 |
Thermo Fisher Scientific
TMO
|
6.72 B | $ 684.39 | 1.57 % | $ 258 B | USA |
 |
Twist Bioscience Corporation
TWST
|
-77.7 M | $ 145.39 | 3.91 % | $ 8.7 B | USA |
 |
Celcuity
CELC
|
-177 M | $ 65.75 | 0.76 % | $ 3.07 B | USA |
 |
VolitionRx Limited
VNRX
|
-23.4 M | $ 0.18 | 0.83 % | $ 22.6 M |  Singapore |
 |
Waters Corporation
WAT
|
643 M | $ 456.36 | 0.39 % | $ 27.2 B | USA |
 |
Exagen
XGN
|
-20 M | $ 7.44 | 2.34 % | $ 160 M | USA |
 |
Quotient Limited
QTNT
|
-125 M | - | -11.32 % | $ 1.1 M | Schweiz |
 |
Chembio Diagnostics
CEMI
|
-23.3 M | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
-101 M | - | -11.32 % | $ 2.94 M | USA |
 |
Surmodics
SRDX
|
-11.5 M | - | - | $ 608 M | USA |
 |
Invitae Corporation
NVTA
|
-99.8 M | - | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
266 M | - | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
-12.9 M | - | -34.28 % | $ 263 K |  Israel |
 |
Castle Biosciences
CSTL
|
-24.2 M | $ 32.84 | -0.73 % | $ 952 M | USA |